PE20020337A1 - IMIDAZOLE DERIVATIVES AS CYCLINE-DEPENDENT KINASE INHIBITORS cdk5 AND cdk2 - Google Patents
IMIDAZOLE DERIVATIVES AS CYCLINE-DEPENDENT KINASE INHIBITORS cdk5 AND cdk2Info
- Publication number
- PE20020337A1 PE20020337A1 PE2001000752A PE2001000752A PE20020337A1 PE 20020337 A1 PE20020337 A1 PE 20020337A1 PE 2001000752 A PE2001000752 A PE 2001000752A PE 2001000752 A PE2001000752 A PE 2001000752A PE 20020337 A1 PE20020337 A1 PE 20020337A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycline
- cdk5
- cdk2
- kinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
SE REFIERE A COMPUESTOS DE FORMULA I EN LA QUE R1 ES UN ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, CICLOALQUILO C3-C8, CICLOALQUENILO C4-C8, O SUSTITUIDOS CON R5, ENTRE OTROS; R2 ES H, F, CH3, CH, COOR7; R3 ES CONR9, COO, -C(=O)(CR10R11)n, ENTRE OTROS; R4 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, CICLOALQUILO C3-C8, CICLOALQUENILO C4-C8, ENTRE OTROS; R5 ES F, Cl, Br, I, NITRO, ENTRE OTROS; R7, R8, R9 SON H, ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, CICLOALQUILO C3-C8, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N-(1-CICLOBUTIL-1H-IMIDAZOL-4-IL)-2-QUINOLIN-6-IL-ACETAMIDA, N-(1-CICLOPENTIL-1H-IMIDAZOL-4-IL)-2-(4-METOXI-FENIL)-ACETAMIDA, N-[1-(CIS-3-FENIL-CICLOBUTIL)-1H-IMIDAZOL-4-IL]-2-QUINOLIN-6-IL-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS DERIVADOS DE IMIDAZOL SON INHIBIDORES DE QUINASA DEPENDIENTES DE CICLINA cdk5 Y cdk2 Y SON UTILES PARA EL TRATAMIENTO DEL CANCER, ENFERMEDADES NEURODEGENERATIVASREFERS TO COMPOUNDS OF FORMULA I IN WHICH R1 IS AN ALKYL C1-C8, ALKYL C2-C8, ALKINYL C2-C8, CYCLOALKYL C3-C8, CYCLOALKENYL C4-C8, OR SUBSTITUTED WITH R5, AMONG OTHERS; R2 IS H, F, CH3, CH, COOR7; R3 IS CONR9, COO, -C (= O) (CR10R11) n, AMONG OTHERS; R4 IS C1-C8 ALKYL, C2-C8 ALKENYL, C2-C8 ALKINYL, C3-C8 CYCLOALKYL, C4-C8 CYCLOALKENYL, AMONG OTHERS; R5 IS F, Cl, Br, I, NITRO, AMONG OTHERS; R7, R8, R9 ARE H, C1-C8 ALKYL, C2-C8 ALKENYL, C2-C8 ALKYL, C3-C8 CYCLOALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE N- (1-CYCLOBUTYL-1H-IMIDAZOL-4-IL) -2-QUINOLIN-6-IL-ACETAMIDE, N- (1-CYCLOPENTIL-1H-IMIDAZOL-4-IL) -2- (4- METHOXY-PHENYL) -ACETAMIDE, N- [1- (CIS-3-PHENYL-CYCLOBUTIL) -1H-IMIDAZOL-4-IL] -2-QUINOLIN-6-IL-ACETAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. IMIDAZOLE DERIVATIVES ARE KINASE INHIBITORS DEPENDENT ON CDK5 AND CDK2 CYCLINE AND ARE USEFUL FOR THE TREATMENT OF CANCER, NEURODEGENERATIVE DISEASES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22172400P | 2000-07-31 | 2000-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020337A1 true PE20020337A1 (en) | 2002-05-08 |
Family
ID=22829075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000752A PE20020337A1 (en) | 2000-07-31 | 2001-07-25 | IMIDAZOLE DERIVATIVES AS CYCLINE-DEPENDENT KINASE INHIBITORS cdk5 AND cdk2 |
Country Status (35)
Country | Link |
---|---|
EP (1) | EP1305295A1 (en) |
JP (2) | JP4166084B2 (en) |
KR (1) | KR20030019644A (en) |
CN (1) | CN1444567A (en) |
AP (1) | AP2001002232A0 (en) |
AR (1) | AR032629A1 (en) |
AU (1) | AU2001270944A1 (en) |
BG (1) | BG107469A (en) |
BR (1) | BR0112862A (en) |
CA (1) | CA2418115A1 (en) |
CR (1) | CR6861A (en) |
CZ (1) | CZ2003225A3 (en) |
DO (1) | DOP2001000220A (en) |
EA (1) | EA200300097A1 (en) |
EC (1) | ECSP034445A (en) |
EE (1) | EE200300049A (en) |
GT (1) | GT200100147A (en) |
HR (1) | HRP20030048A2 (en) |
HU (1) | HUP0303069A3 (en) |
IL (1) | IL153787A0 (en) |
IS (1) | IS6662A (en) |
MA (1) | MA26932A1 (en) |
MX (1) | MXPA03000939A (en) |
NO (1) | NO20030472L (en) |
NZ (1) | NZ523272A (en) |
OA (1) | OA12345A (en) |
PA (1) | PA8523701A1 (en) |
PE (1) | PE20020337A1 (en) |
PL (1) | PL365134A1 (en) |
SK (1) | SK1042003A3 (en) |
SV (1) | SV2002000571A (en) |
TN (1) | TNSN01114A1 (en) |
UY (1) | UY26862A1 (en) |
WO (1) | WO2002010141A1 (en) |
ZA (1) | ZA200300819B (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (en) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS |
EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
EP1527070B1 (en) | 2002-06-14 | 2013-01-09 | Merck Serono SA | Azole methylidene cyanide derivatives and their use as protein kinase modulators |
DE10233817A1 (en) * | 2002-07-25 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
US7141561B2 (en) | 2002-07-25 | 2006-11-28 | Sanofi-Aventis Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
PT1626714E (en) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diaryl ureas for diseases mediated by pdgfr |
SI1663978T1 (en) | 2003-07-23 | 2008-02-29 | Bayer Pharmaceuticals Corp | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
CA2560580C (en) * | 2004-03-23 | 2008-12-23 | Pfizer Products Inc. | Imidazole compounds for inhibition of a.beta.-peptide production and for modulation of the notch signaling pathway |
ATE517885T1 (en) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES FOR THE TREATMENT OF CANCER |
US7928264B2 (en) | 2004-09-21 | 2011-04-19 | Astellas Pharma Inc. | Aminoalcohol derivatives |
WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
EP1940802A2 (en) | 2005-09-22 | 2008-07-09 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
JP2009512711A (en) | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Regulation of neurogenesis by PDE inhibition |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
CA2636077C (en) | 2006-01-18 | 2012-01-03 | Amgen Inc. | Thiazole compounds as protein kinase b (pkb) inhibitors |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
MX2009004140A (en) | 2006-10-21 | 2009-07-10 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors. |
WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
CN102015718B (en) * | 2008-04-24 | 2014-12-10 | Abbvie德国有限责任两合公司 | 1- (7-(hexahydropyrrolo [3, 4-C] pyrrol-2 (1H) -yl) quin0lin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3) |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
JP5998142B2 (en) | 2010-09-27 | 2016-09-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
MX2015007051A (en) | 2012-12-07 | 2016-01-12 | Chemocentryx Inc | Diazole lactams. |
CN104918921B (en) * | 2012-12-21 | 2017-09-22 | 凯莫森特里克斯股份有限公司 | Diazole acid amides |
JP6616190B2 (en) * | 2014-02-07 | 2019-12-04 | 国立大学法人 東京医科歯科大学 | Muscle formation promoter, muscle atrophy inhibitor, pharmaceutical composition, and TAZ activator |
WO2017040611A1 (en) | 2015-08-31 | 2017-03-09 | Nutramax Laboratories, Inc. | Compositions comprising magnolia, phellodendron, theanine and/or whey protein |
GB201605126D0 (en) | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
AU2017246460B2 (en) | 2016-04-07 | 2021-04-22 | Chemocentryx, Inc. | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors |
CN107698567B (en) * | 2017-10-25 | 2020-09-15 | 西南大学 | Isatin azole alcohol compound and preparation method and medical application thereof |
WO2020163812A1 (en) | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
GB201908424D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
US10590087B1 (en) | 2019-08-09 | 2020-03-17 | Pfizer Inc. | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
CN112250636A (en) * | 2020-11-09 | 2021-01-22 | 广西科技大学 | 5-aminoimidazole compound and synthesis method thereof |
US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
ZA987383B (en) * | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
ZA987385B (en) * | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
CN1312807A (en) * | 1998-06-19 | 2001-09-12 | 希龙公司 | Inhibitors of glycogen synthase kinase 3 |
WO2000021550A2 (en) * | 1998-10-13 | 2000-04-20 | President And Fellows Of Harvard College | Methods and compositions for treating neurodegenerative diseases |
CO5160260A1 (en) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | SECRETAGOGOS OF THE HORMONE OF GROWTH DERIVED FROM IMI- DAZOL 1,4- SUBSTITUTED |
DE69912808T2 (en) * | 1999-12-08 | 2004-09-30 | Centre National De La Recherche Scientifique (C.N.R.S.) | Use of hymenialdisine and its derivatives for the preparation of therapeutic agents |
-
2001
- 2001-07-23 GT GT200100147A patent/GT200100147A/en unknown
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/en active IP Right Grant
- 2001-07-25 CN CN01813397A patent/CN1444567A/en active Pending
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Application Discontinuation
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/en not_active Application Discontinuation
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/en not_active IP Right Cessation
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 EA EA200300097A patent/EA200300097A1/en unknown
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/en not_active Expired - Fee Related
- 2001-07-25 IL IL15378701A patent/IL153787A0/en unknown
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-25 PL PL01365134A patent/PL365134A1/en not_active Application Discontinuation
- 2001-07-25 EE EEP200300049A patent/EE200300049A/en unknown
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/en not_active Application Discontinuation
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/en unknown
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/en unknown
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/en not_active Application Discontinuation
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/en unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/en not_active Application Discontinuation
- 2001-07-30 AR ARP010103637A patent/AR032629A1/en unknown
- 2001-07-30 UY UY26862A patent/UY26862A1/en not_active Application Discontinuation
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/en unknown
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/en unknown
-
2002
- 2002-12-18 CR CR6861A patent/CR6861A/en not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/en unknown
-
2003
- 2003-01-16 BG BG107469A patent/BG107469A/en unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/en unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/en unknown
- 2003-01-24 HR HR20030048A patent/HRP20030048A2/en not_active Application Discontinuation
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/en not_active Application Discontinuation
-
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/en not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020337A1 (en) | IMIDAZOLE DERIVATIVES AS CYCLINE-DEPENDENT KINASE INHIBITORS cdk5 AND cdk2 | |
PE20191755A1 (en) | PYRAZOLE DERIVATIVES AS MALT 1 INHIBITORS | |
UY29633A1 (en) | OXINDOL DERIVATIVES | |
PE20230238A1 (en) | KRAS G12C INHIBITORS | |
AR049578A1 (en) | HYDANTOIN DERIVATIVES, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS | |
CU23550B7 (en) | PIRROLO-PIRAZOL DERIVATIVES REPLACED AS QUINASA INHIBITORS | |
AR056860A1 (en) | TRIAZOL DERIVATIVES INHIBITORS OF QUINASA TGF-BETA1 RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES FOR TUMOR TREATMENT | |
PE20050330A1 (en) | 3,5-DISUSTITUTED INDAZOLE COMPOUNDS AS CYCLINE-DEPENDENT KINASE INHIBITORS (CDK) | |
PE20020469A1 (en) | NUCLEOTIDE POLICYCLICS AS INHIBITORS OF XANTHINE PHOSPHODIESTERASE V | |
PE20020504A1 (en) | APOPTOSIS-PROMOTING N-ACILSULFONAMIDES | |
PE20050462A1 (en) | COMPOUNDS OF 5,7-DIAMINOPYRAZOLE [4,3-d] PYRIMIDINES AS INHIBITORS OF PHOSPHODIESTERASE TYPE 5 (PDE-5) | |
AR041184A1 (en) | DERIVATIVES OF BENZOPIRANONAS, INHIBITORS OF CYCLINE DEPENDENT KINES AND THEIR USE | |
AR057109A1 (en) | BENZIMIDAZOLS REPLACED AND METHODS TO USE THEM AS INHIBITORS OF KINASES ASSOCIATED WITH TUMORIGENESIS | |
ECSP078003A (en) | ASPARTIL PROTEASAS INHIBITORS | |
UY30316A1 (en) | SUBSTITUTED DERIVATIVES OF BENZAMIDS, NICOTINAMIDS, PROPANAMIDS, ACETAMIDS AND CARBOXAMIDS N- (2- (PIPERIDIN-1-ILMETIL) CICLOHEXIL) REPLACED, PREPARATION PROCESSES, COMPOSITIONS CONTAINING AND APPLICATIONS | |
UY29087A1 (en) | ADAMANTILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USE | |
AR048642A1 (en) | METHYL-ARIL OR HETEROARIL-AMIDA SUBSTITUTED COMPOUNDS USEFUL AS ANTAGONISTS OF THE E2 PROSTAGLANDIN RECEIVER; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT | |
AR053554A1 (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | |
ECSP045473A (en) | DERIVATIVES OF 1- (AMINOALQUIL) -3-SULFONYLINDOL AND 1-AMINOALQUIL-3-SULFONYLINDAZOL AS 5-HYDROXYTHYRIPTAMINE-6 LIGANDS | |
CY1107677T1 (en) | Derivatives of 1- [INDOL-3-YL) CARBONYL] PIPERAZINE | |
AR051795A1 (en) | HYDANTOIN DERIVATIVES METALOPROTEINASE INHIBITORS | |
UY29370A1 (en) | DERIVATIVES OF TIAZOL, COMPOSITIONS THAT CONTAIN IT, PREPARATION PROCEDURES AND APPLICATIONS | |
PE20081315A1 (en) | BENZIMIDAZOLE DERIVATIVES AS ANTAGONISTS OF VR-1 | |
PE20200446A1 (en) | NEW SELECTIVE HDAC6 INHIBITORS | |
PE20070212A1 (en) | 1,4-DIHYDROPYRIDINE-CONDENSED HETEROCYCLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |